WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Resources > Infographics > Synthetic Biology
January 1, 2017
I'm For Real
Enter your details once to access all our information and resources
A global biopharmaceutical company specialized in research, development and manufacturing of biosimilars for the treatment and/or prevention of several diseases in diverse therapeutic areas.
Infographic | August 12, 2022
The field (gene therapy) is not standing still, it’s evolving rapidly. If we have this discussion again in 18 months’ time, I don't know what we’ll be using then.
Infographic | April 13, 2020
Near the turn of the millennium, James Collins and Stanislas Leibler independently undertook rather similar projects: design what would become synthetic biology’s seminal genetic circuits. And they came up with strikingly similar action plans—use E. coli to pair promoters with repressors that control one another’s behavior.
Infographic | April 7, 2020
As part of our In Focus on RNA sequencing for cancer research, we put together an infographic to provide top tips on the preparation of RNA sequencing libraries, the best metrics to use when analyzing your libraries and suggestions for efficient and effective kits for the preparation of each library type.
Infographic | August 23, 2021
As per the study, the global Bioinformatics market was valued at $3.4 billion in 2013, and it is expected to reach $12.8 billion by 2020. The market is expected to grow at a CAGR of 21.2% during 2014-2020
Infographic | August 5, 2021
Europe continues to be a powerhouse of science and innovation. The region maintains a clear lead over China, the United States, and the rest of the world in terms of the quality and quantity of its science. For example, Europe is home to 43 of the global top 100 life-science universities, while the United States has 34. Europe is a powerhouse in scientific publishing as well, with roughly twice the output of the United States and three times that of China.Europe also leads in terms of quality, as measured by the number of citations for its publications. More than 40,000 biotech patents have been granted in Europe since 2015, although the region’s 3 percent CAGR in patent approvals between 2015 and 2019 lagged behind that of the United States (4 percent) and was a fraction of China’s (14 percent).Despite Europe’s strength in science and innovation, translation remains the biggest challenge. Translation of science into companies is stagnant. The distribution of newly funded biotechs remains unchanged across geographies over the last six years, and Europe accounts for only 25 percent of new biotechs. Future success will depend on improving the translation of research into new companies, raising more capital, and building entrepreneurial talent.
Infographic | December 1, 2019
Discovering a new type of subnuclear body taught me how pursuing the unexpected can lead to new insights—in this case, about long noncoding RNAs and liquid-liquid phase separation in cells.
Europe continues to be a powerhouse of science and innovation. The region maintains a clear lead over China, the United States, and the rest of the world in terms of the quality and quantity of its science. For example, Europe is home to 43 of the global top 100 life-science universities, while the United States has 34. Europe is a powerhouse in scientific publishing as well, with roughly twice the output of the United States and three times that of China. Europe also leads in terms of quality, as measured by the number of citations for its publications. More than 40,000 biotech patents have been granted in Europe since 2015, although the region’s 3 percent CAGR in patent approvals between 2015 and 2019 lagged behind that of the United States (4 percent) and was a fraction of China’s (14 percent). Despite Europe’s strength in science and innovation, translation remains the biggest challenge. Translation of science into companies is stagnant. The distribution of newly funded biotechs remains unchanged across geographies over the last six years, and Europe accounts for only 25 percent of new biotechs. Future success will depend on improving the translation of research into new companies, raising more capital, and building entrepreneurial talent.
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE